Buy out firms TPG, CPP to acquire IMS Health for $5.2 billion

06 Nov 2009

1

Health care market research and consulting company IMS Health yesterday agreed to sell itself to private equity firms TPG Capital and the CPP Investment Board in a transaction valued at $5.2 billion, including debt.

Operating for more than 50 years and having offices in more than 100 countries, IMS is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With $2.3 billion in 2008 revenue IMS offers leading-edge market intelligence products and services and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide.

Stockholders of Norwalk, Connecticut-based IMS will receive $22.00 cash for each share of IMS common stock they own, representing a premium of approximately 50 per cent over the closing share price on Friday, 16 October 2009, the last trading day prior to public speculation that IMS was considering its strategic alternatives.

The transaction has fully committed financing, consisting of a combination of equity to be invested by TPG and CPPIB and debt financing to be provided by certain affiliates of Goldman, Sachs & Co., including its principal loan and mezzanine funds.

The transaction includes Fort Worth, Texas-based TPG and Toronto-based CPPIB taking on IMS debt of $1.34 billion. The company had cash and equivalents of $301.7 million as of 30 September, according to IMS statement last month.

''This transaction enables our shareholders to realisc substantial value from their investment in IMS with an immediate cash premium, while at the same time strengthening our position to capture long-term growth opportunities,'' said IMS chairman and CEO David Carlucci.

Latest articles

Carmakers explore energy storage, but claims of major pivot and write-downs are overstated

Carmakers explore energy storage, but claims of major pivot and write-downs are overstated

Government advances Dholera semiconductor hub, but timelines and scale claims need caution

Government advances Dholera semiconductor hub, but timelines and scale claims need caution

South Korea’s AI chip push grows, but 2nm robotics claims remain premature

South Korea’s AI chip push grows, but 2nm robotics claims remain premature

India–Japan chip collaboration grows, but details around Axiro–EdgeCortix deal remain limited

India–Japan chip collaboration grows, but details around Axiro–EdgeCortix deal remain limited

Post-splashdown: What Artemis II taught us about the ‘deep space wall’

Post-splashdown: What Artemis II taught us about the ‘deep space wall’

Carmakers explore energy storage, but claims around Ford and GM pivot remain overstated

Carmakers explore energy storage, but claims around Ford and GM pivot remain overstated

Tesla’s robotics push continues, but Shanghai “Optimus mass production” claims remain unconfirmed

Tesla’s robotics push continues, but Shanghai “Optimus mass production” claims remain unconfirmed

VinFast eyes India growth, but details around VF MPV 7 launch remain unverified

VinFast eyes India growth, but details around VF MPV 7 launch remain unverified

Breaking the engine barrier: HAL and GE move forward on F414 co-production deal

Breaking the engine barrier: HAL and GE move forward on F414 co-production deal